



## Zymeworks to Present at Stifel 2019 Healthcare Conference

November 4, 2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present at the upcoming Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York, NY.

The Company's presentation will be on Tuesday, November 19, 2019 at 8:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit [www.zymeworks.com](http://www.zymeworks.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20191104005136/en/): <https://www.businesswire.com/news/home/20191104005136/en/>

### Zymeworks Inc.

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[\[email protected\]](#)

Tiffany Tolmie  
(604) 678-1388  
[\[email protected\]](#)

Media Inquiries:  
Kavita Shah, Ph.D.  
(604) 678-1388  
[\[email protected\]](#)

Source: Zymeworks Inc.